Managing Treatment-Resistant Depression: Road to Novel Therapeutics defines TRD for readers, discussing the clinical and epidemiological predictors, economic burden and neurobiological factors. In addition, staging methods for treatment resistance are fully covered in this book, including serotonin specific reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, other classes of antidepressants, including tricyclic antidepressants and monoamine oxidase inhibitors, augmentation strategies, and newer antidepressant treatments like ketamine and esketamine. In addition, evidence supporting the use of psychotherapies and neuromodulation strategies are also reviewed. Written by top experts in the field, this book is the first of its kind to review all methods of treatment for TRD.
Edited by:
Joao Quevedo MD PhD (Professor of Psychiatry at the McGovern Medical School The University of Texas Health Science Center at Houston TX USA),
Patricio Riva-Posse (Emory University,
Atlanta,
GA,
USA),
William V. Bobo (Mayo Clinic,
Jacksonville,
FL,
USA)
Imprint: Academic Press Inc
Country of Publication: United States
Dimensions:
Height: 276mm,
Width: 216mm,
Weight: 1.650kg
ISBN: 9780128240670
ISBN 10: 0128240679
Pages: 612
Publication Date: 04 April 2022
Audience:
Professional and scholarly
,
Undergraduate
Format: Paperback
Publisher's Status: Active
1. Defining treatment-resistant depression, difficult-to-treat depression, and staging treatment intensity 2. Clinical and epidemiological predictors of treatment-resistant depression 3. The economic burden of treatment-resistant depression: Cost-of-illness perspective 4. The neurobiology of treatmentresistant depression 5. Modeling treatment-resistant depression in the preclinical setting 6. Treatment algorithms for treatment-resistant depression 7. Tools to aid precision treatments to prevent or manage treatmentresistant depression (TRD): Pharmacogenomics, machine learning, and artificial intelligence 8. Tricyclic antidepressants for treatment-resistant depression 9. Monoamine oxidase inhibitors for treatment-resistant depression 10. Switching antidepressants in patients with treatment-resistant depression 11. Adjunctive strategies for treatment-resistant depression 12. Combining antidepressants to address treatment-resistant depression 13. Ketamine/esketamine for treatment-resistant depression 14. Psychedelic agents for treatmentresistant depression 15. Inflammation and treatment resistance: Mechanisms and treatment implications 16. Opioid agents for treatmentresistant depression 17. Transcranial magnetic stimulation for treatment-resistant depression 18. tDCS for treatment-resistant depression 19. ECT for treatment-resistant depression 20. MST for treatment-resistant depression 21. VNS for treatment-resistant depression 22. Deep brain stimulation for treatment-resistant depression 23. Other neurosurgical interventions for treatment-resistant depression 24. Treatment-resistant psychotic depression 25. Evidence-based psychotherapy for treatment-resistant depression 26. Treatment-resistant bipolar depression 27. Treatment-resistant depression in child and adolescents 28. Treatment-resistant depression in geriatrics 29. Identification and management of anxious depression in patients with treatment-resistant depression 30. Managing treatment-resistant depression with comorbid personality disorders 31. Managing treatment-resistant depression with comorbid substance use disorders 32. Managing treatment-resistant depression in the setting of chronic pain 33. Inhaled gases for treatmentresistant major depression 34. Drugs under investigation for treatment-resistant depression 35. Chronotherapeutics for treatmentresistant depression 36. Managing treatment resistant depression in primary care settings 37. Treatment-resistant depression in pregnancy, the postpartum period, and transition to menopause 38. Lifestyle interventions for treatment-resistant depression 39. Managing the risk of suicide in people with treatment-resistant depression 40. Maintaining motivation and preserving the therapeutic alliance as tools to overcome treatmentresistant depression
Dr. João Luciano de Quevedo, MD, PhD, is a Professor of Psychiatry at the McGovern Medical School, the University of Texas Health Science Center at Houston, where he is the Vice-Chair for Faculty Development and Outreach, Director of the Translational Psychiatry Program, and Director of the Treatment-Resistant Depression Clinic. Before moving to Houston, he was a Dean at the University of Southern Santa Catarina Medical School, Criciúma, SC, Brazil, where he is still an Adjunct Professor of Psychiatry. He is also Editor-in-Chief of the Brazilian Journal of Psychiatry and Director of the Continuous Medical Education Program in Psychiatry (PROPSIQ) of the Brazilian Psychiatric Association. Dr. Quevedo’s research interest is neurobiology of psychiatric disorders, particularly mood disorders, and he is a specialist in both unipolar and bipolar treatment–resistant depression. He is author of nearly 600 publications and 10 scientific books. Dr. Patricio Riva-Posse, MD is an Assistant Professor in the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine. After completing his training in Neurology and in Psychiatry, he has focused his clinical and research work in the field of treatment resistant mood disorders. He is the Director of the Treatment Resistant Depression Clinic, and Director of Neuromodulation Services. He conducts research in invasive and non-invasive neuromodulation as well as novel pharmacological approaches. He is an investigator in NIH-funded project studying subcallosal cingulate deep brain stimulation. Born in Argentina, he earned his Medical Doctor degree from the Universidad de Buenos Aires. Dr. William V. Bobo, M.D., M.P.H., is Professor of Psychiatry at the Mayo Clinic Alix School of Medicine and Chair, Department of Psychiatry & Psychology at Mayo Florida, where he also serves as the Medical Director for Leadership Development. His clinical and research interests are focused on the treatment of patients with refractory mood disorders and on examining and predicting the clinical effects — both beneficial and harmful--of medications used to treat people with severe mood disorders. He lives with his wife in Jacksonville, Florida.
